Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

NCT03758950 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Placebo
DRUG: Mometasone

Sponsor

Jeffrey Glassberg

Collaborators

[object Object]